Xcellerex sells FlexFactory line to R-Pharm
Will fast track R-Pharm’s entry into biologics manufacturing
Russian pharmaceutical company R-Pharm has bought a 2,000L FlexFactory bioproduction line from Xcellerex for its new biologics manufacturing facility in Yaroslavl. The facility, R-Pharm’s first entry into large-scale manufacturing of biologics in Russia, will dramatically accelerate its production timeline. Financial terms were not disclosed.
Alexey Repik, chairman of R-Pharm, which is based in Moscow, said the FlexFactory would fast track its entry into biologics manufacturing.
‘Biologics are revolutionising the treatment of many diseases. R-Pharm has made a strategic commitment to producing these advanced medicines locally to increase their access and affordability to the Russian people. The FlexFactory and the expertise that Xcellerex are providing will significantly accelerate our development and commercial timelines,’ he said.
R-Pharm expects to begin production in the FlexFactory next year.
Guy Broadbent, chief executive of Xcellerex, which is based in Marlborough, Massachusetts, US, said the agreement is an important first step in its strategy to play an enabling role in the coming wave of Russian investment in biomanufacturing capacity.
Under the agreement, Xcellerex will provide R-Pharm with the FlexFactory production line, along with extensive bioprocess services and training to ensure rapid and efficient transfer of technology and expertise to support cGMP operations that meet global regulatory requirements.
The FlexFactory is a complete modular and portable production train based on single-use technologies, advanced process automation, and compact cleanroom architecture.
